Internal Medicine, Endocrinology, Diabetes, & Metabolism · South Pasadena, CA
NPI
1043277601
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
209 Fair Oaks Ave
South Pasadena, CA, 91030
Phone (626) 396-2900
Groups this clinician bills Medicare through
Medicare paid, 2024
$326K
14,313 services
Medicare patients, 2024
622
Average age 75
Drug cost, 2024
$2.4M
5,954 prescriptions
Company payments, 2025
$2,224
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Wei Feng was code J0897 (injection, denosumab, 1 mg), 6,480 times for 67 patients. In total Wei Feng billed 14,313 services in 28 codes, and Medicare paid $326K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-12-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 6,480 | 67 | $20.28 | $131K |
| 99214 Office E&M - Established | Office | 956 | 495 | $103.20 | $99K |
| 96372 Injection Administration | Office | 138 | 77 | $13.02 | $1,797 |
| 99204 Office E&M - New | Office | 126 | 126 | $132.12 | $17K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 100 | 20 | $4.53 | $453 |
| 99214 Office E&M - Established | Facility | 77 | 47 | $73.49 | $5,659 |
| 99213 Office E&M - Established | Office | 58 | 50 | $76.03 | $4,409 |
| 96365 Intravenous Infusion, Hydration | Office | 21 | 21 | $53.76 | $1,129 |
| 99215 Office E&M - Established | Office | 14 | 14 | $151.32 | $2,119 |
By year: 2022 $302K for 15,501 services; 2023 $336K for 13,637 services; 2024 $326K for 14,313 services.
Medicare prescription drug claims, 2024
In 2024, the drug Wei Feng prescribed most often to Medicare patients was Levothyroxine Sodium, with 506 prescriptions and refills. In total Wei Feng wrote 5,954 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 506 | 1,085 | 111 | $5,175 |
| Jardiance Empagliflozin | 328 | 455 | 49 | $256K |
| Synthroid Levothyroxine Sodium | 290 | 593 | 64 | $26K |
| Ozempic Semaglutide | 274 | 331 | 37 | $304K |
| Farxiga Dapagliflozin Propanediol | 264 | 381 | 46 | $210K |
| Metformin Hcl Generic | 259 | 520 | 57 | $3,322 |
| Atorvastatin Calcium Generic | 244 | 546 | 62 | $2,213 |
| Januvia Sitagliptin Phosphate | 187 | 236 | 33 | $126K |
| Metformin Hcl Er Metformin Hcl | 176 | 396 | 47 | $2,078 |
| Alendronate Sodium Generic | 155 | 293 | 36 | $985 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 130 | 230 | 38 | $12K |
| Rosuvastatin Calcium Generic | 123 | 245 | 31 | $1,864 |
| Tradjenta Linagliptin | 111 | 127 | 19 | $63K |
| Losartan Potassium Generic | 98 | 217 | 22 | $1,281 |
| Trulicity Dulaglutide | 93 | 118 | 16 | $115K |
Brand drugs: 2,731 claims; generic drugs: 2,934 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Wei Feng $2,224 ($2,224 in general payments such as food, travel and fees) from 11 companies. The largest payer was Abbott Laboratories with $506.
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories ABT | 10 | $506 |
| Amgen Inc. AMGN | 16 | $367 |
| Chiesi USA, Inc. | 1 | $300 |
| Novo Nordisk Inc NVO | 3 | $251 |
| Radius Health, Inc. | 12 | $171 |
| Insulet Corporation PODD | 4 | $160 |
| Ascendis Pharma Endocrinology Inc ASND | 1 | $125 |
| Kyowa Kirin, Inc. 4151.T | 1 | $122 |
| Beta Bionics, Inc. BBNX | 2 | $94.88 |
| Madrigal Pharmaceuticals MDGL | 4 | $68.91 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.